NZ628292A - Pluripotent germ layer origin antigen presenting cancer vaccine - Google Patents
Pluripotent germ layer origin antigen presenting cancer vaccineInfo
- Publication number
- NZ628292A NZ628292A NZ628292A NZ62829213A NZ628292A NZ 628292 A NZ628292 A NZ 628292A NZ 628292 A NZ628292 A NZ 628292A NZ 62829213 A NZ62829213 A NZ 62829213A NZ 628292 A NZ628292 A NZ 628292A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- gamma
- antigen presenting
- cancer vaccine
- cancer cells
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 238000009566 cancer vaccine Methods 0.000 title 1
- 210000001654 germ layer Anatomy 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 11
- 201000011510 cancer Diseases 0.000 abstract 11
- 210000004027 cell Anatomy 0.000 abstract 7
- 102000008070 Interferon-gamma Human genes 0.000 abstract 5
- 108010074328 Interferon-gamma Proteins 0.000 abstract 5
- 229960003130 interferon gamma Drugs 0.000 abstract 5
- 210000004443 dendritic cell Anatomy 0.000 abstract 3
- 238000000338 in vitro Methods 0.000 abstract 3
- 230000002886 autophagic effect Effects 0.000 abstract 2
- 201000001441 melanoma Diseases 0.000 abstract 2
- 230000004987 nonapoptotic effect Effects 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4272—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594304P | 2012-02-02 | 2012-02-02 | |
| PCT/US2013/024123 WO2013116505A1 (en) | 2012-02-02 | 2013-01-31 | Pluripotent germ layer origin antigen presenting cancer vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ628292A true NZ628292A (en) | 2016-09-30 |
Family
ID=48905824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ628292A NZ628292A (en) | 2012-02-02 | 2013-01-31 | Pluripotent germ layer origin antigen presenting cancer vaccine |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150064217A1 (enExample) |
| EP (1) | EP2809775B1 (enExample) |
| JP (1) | JP2015506698A (enExample) |
| KR (1) | KR20140143361A (enExample) |
| CN (1) | CN104540937A (enExample) |
| AU (1) | AU2013215116A1 (enExample) |
| CA (1) | CA2863653A1 (enExample) |
| GB (1) | GB2512558A (enExample) |
| HK (2) | HK1209455A1 (enExample) |
| IL (1) | IL233928A0 (enExample) |
| NZ (1) | NZ628292A (enExample) |
| SG (1) | SG11201404543UA (enExample) |
| WO (2) | WO2013116541A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599528B (zh) * | 2013-12-04 | 2015-08-05 | 深圳市合一康生物科技股份有限公司 | 人树突状细胞疫苗的制备方法 |
| JP6423889B2 (ja) | 2014-10-07 | 2018-11-14 | サイトリミック株式会社 | Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
| EP3527216B1 (en) | 2016-10-11 | 2024-02-14 | NEC Corporation | A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide |
| CN110198717A (zh) * | 2017-01-11 | 2019-09-03 | 国立研究开发法人国立癌症研究中心 | 免疫治疗药 |
| EP3582793A4 (en) * | 2017-02-17 | 2020-12-16 | Aivita Biomedical, Inc. | METHODS TO IMPROVE TUMOR IMMUNOGENICITY AND COMPOSITIONS FOR AUTOLOGOUS ANTI-CANCER IMMUNOTHERAPEUTICS USING MODIFIED TUMOR CELLS AND MODIFIED DENDRITIC CELLS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL140796A0 (en) * | 2001-01-08 | 2002-02-10 | Hadasit Med Res Service | An autologous anti-cancer vaccine |
| EP2322603B1 (en) * | 2001-09-06 | 2019-10-16 | NorthWest Biotherapeutics, Inc. | Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response |
| WO2006047515A2 (en) * | 2004-10-25 | 2006-05-04 | Baylor Research Institute | Dendritic cells loaded with heat shocked melanoma cell bodies |
| JP5281399B2 (ja) * | 2005-07-29 | 2013-09-04 | プロビデンス ヘルス システム | 小胞（ｄｒｉｂｂｌｅ）中の不完全なリボソーム産物、および免疫応答を刺激するための使用方法 |
| WO2008039974A2 (en) * | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| US20090041792A1 (en) * | 2007-07-19 | 2009-02-12 | Istituto Superiore Di Sanita | Dendritic cells, uses therefor, and vaccines and methods comprising the same |
-
2013
- 2013-01-31 CN CN201380017689.2A patent/CN104540937A/zh active Pending
- 2013-01-31 HK HK15110097.4A patent/HK1209455A1/xx unknown
- 2013-01-31 NZ NZ628292A patent/NZ628292A/en not_active IP Right Cessation
- 2013-01-31 GB GB1414403.4A patent/GB2512558A/en not_active Withdrawn
- 2013-01-31 CA CA2863653A patent/CA2863653A1/en not_active Abandoned
- 2013-01-31 EP EP13743673.9A patent/EP2809775B1/en not_active Not-in-force
- 2013-01-31 KR KR1020147024678A patent/KR20140143361A/ko not_active Ceased
- 2013-01-31 US US14/375,966 patent/US20150064217A1/en not_active Abandoned
- 2013-01-31 HK HK15103009.6A patent/HK1202432A1/xx unknown
- 2013-01-31 SG SG11201404543UA patent/SG11201404543UA/en unknown
- 2013-01-31 WO PCT/US2013/024181 patent/WO2013116541A1/en not_active Ceased
- 2013-01-31 WO PCT/US2013/024123 patent/WO2013116505A1/en not_active Ceased
- 2013-01-31 AU AU2013215116A patent/AU2013215116A1/en not_active Abandoned
- 2013-01-31 JP JP2014555705A patent/JP2015506698A/ja active Pending
-
2014
- 2014-08-03 IL IL233928A patent/IL233928A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL233928A0 (en) | 2014-09-30 |
| WO2013116505A1 (en) | 2013-08-08 |
| GB201414403D0 (en) | 2014-10-01 |
| CN104540937A (zh) | 2015-04-22 |
| SG11201404543UA (en) | 2014-08-28 |
| US20150064217A1 (en) | 2015-03-05 |
| EP2809775A4 (en) | 2015-07-01 |
| HK1202432A1 (en) | 2015-10-02 |
| GB2512558A (en) | 2014-10-01 |
| KR20140143361A (ko) | 2014-12-16 |
| CA2863653A1 (en) | 2013-08-08 |
| HK1209455A1 (en) | 2016-04-01 |
| EP2809775A1 (en) | 2014-12-10 |
| EP2809775B1 (en) | 2018-06-13 |
| WO2013116541A1 (en) | 2013-08-08 |
| AU2013215116A1 (en) | 2014-08-21 |
| JP2015506698A (ja) | 2015-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4286511A3 (en) | Method to treat cancer with engineered t-cells | |
| EP4495133A3 (en) | Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation | |
| MX2023001403A (es) | Neoantigenos y metodos de su uso. | |
| CL2017001819A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer | |
| SG10201808258SA (en) | Improved methods for manufacturing adoptive cell therapies | |
| MX2019003616A (es) | Celulas beta derivadas de celulas madre (sc-beta) y composiciones y metodos para generarlas. | |
| WO2016070166A3 (en) | Messenger una molecules and uses thereof | |
| WO2016090178A3 (en) | Processes for producing exosomes in reduced oxygen culture conditions | |
| NZ715201A (en) | Afucosylated anti-fgfr2iiib antibodies | |
| BR112017011215A2 (pt) | partículas de distribuição de pró-flavorizante | |
| CR20210464A (es) | Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido en carcinoma del pulmón amicrocítico (nsclc) | |
| WO2013006474A3 (en) | Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127 | |
| MX374472B (es) | Composiciones y métodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva. | |
| MX2019009386A (es) | Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer. | |
| EP4219690A3 (en) | Methods of cancer treatment using activated t cells | |
| PH12020500433A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| CA2866116C (en) | Expansion of alloantigen-reactive regulatory t cells | |
| WO2018185709A9 (en) | Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof | |
| NZ628292A (en) | Pluripotent germ layer origin antigen presenting cancer vaccine | |
| PH12019502036A1 (en) | Peptides and methods for the treatment of diabetes | |
| NZ594198A (en) | Neil3 peptides and vaccines including the same | |
| MX375994B (es) | Composicion farmaceutica que comprende particulas de plga-peg. | |
| MX2012013875A (es) | Anticuerpos de union sparc en sangre periferica y usos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: NEOSTEM ONCOLOGY, LLC, US Effective date: 20140918 Owner name: NBS ACQUISITION SUB II, LLC, US Effective date: 20140904 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JAN 2018 BY CPA GLOBAL Effective date: 20170324 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JAN 2019 BY CPA GLOBAL Effective date: 20171214 |
|
| ASS | Change of ownership |
Owner name: CALADRIUS BIOSCIENCES, INC., US Effective date: 20180123 |
|
| LAPS | Patent lapsed |